Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
GERN · against 479 other Healthcare companies of similar size
Ranked #311 of 480 · scores higher than 12% of peers
Bars: peers in each 10-point band of the valuation score170 peers with a valuation score of 0–9, including GERN · Click a bar to see the companies
Mainly because of its free cash flow yield, earnings yield and EBITDA yield, which are weaker than most Healthcare peers.
| Metric | GERN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 468 reported | -11.8% | 0.6% | 18% | 30% | |
| EBITDA yieldHigher is better · 485 reported | -8.3% | 3.5% | 20% | 50% | |
| Free cash flow yieldHigher is better · 203 reported | -19.2% | -5.0% | 18% | 20% | |
| Book yieldHigher is better · 480 reported | 36.6% | 45.6% | 39% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 311 | 508M EUR (≈$559M) | 8 | 21 | |
| 311 | 660M USD | 8 | 43 | |
| 311 | 375M USD | 8 | 46 | |
| 311 | 533M USD | 8 | 36 | |
| 311 | 598M USD | 8 | 49 | |
| 311 | 888M USD | 8 | 25 | |
| 311 | 471M USD | 8 | 21 | |
| 311 | 660M USD | 8 | ||
| 311 | 1.1B USD | 8 | 32 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score